These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35536994)

  • 21. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
    Fathi AT; Blonquist TM; Hernandez D; Amrein PC; Ballen KK; McMasters M; Avigan DE; Joyce R; Logan EK; Hobbs G; Brunner AM; Joseph C; Perry AM; Burke M; Behnan T; Foster J; Bergeron MK; Moran JA; Ramos AY; Som TT; Rae J; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Levis MJ
    Cancer; 2018 Jan; 124(2):306-314. PubMed ID: 28960265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
    Tannir NM; Schwab G; Grünwald V
    Curr Oncol Rep; 2017 Feb; 19(2):14. PubMed ID: 28247252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.
    Lev A; Deihimi S; Shagisultanova E; Xiu J; Lulla AR; Dicker DT; El-Deiry WS
    Cancer Biol Ther; 2017 Sep; 18(9):694-704. PubMed ID: 28886275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
    Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
    Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cabozantinib: Mechanism of action, efficacy and indications].
    Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
    Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
    Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
    PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
    Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
    Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic alterations in signet ring and mucinous patterned colorectal carcinoma.
    Kim H; Kim BH; Lee D; Shin E
    Pathol Res Pract; 2019 Oct; 215(10):152566. PubMed ID: 31400926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
    Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
    Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma.
    Deeks ED
    Target Oncol; 2019 Feb; 14(1):107-113. PubMed ID: 30767164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor Activity of Cabozantinib in Metastatic Adult Ewing Sarcoma: A Case Report.
    Schallier D; Lesfevre P; Everaert H
    Anticancer Res; 2020 Apr; 40(4):2265-2269. PubMed ID: 32234924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.
    Sandhu J; Wang C; Fakih M
    J Natl Compr Canc Netw; 2020 Feb; 18(2):116-119. PubMed ID: 32023524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Brose MS; Robinson B; Sherman SI; Krajewska J; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Hernando J; Faoro L; Banerjee K; Oliver JW; Keam B; Capdevila J
    Lancet Oncol; 2021 Aug; 22(8):1126-1138. PubMed ID: 34237250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline Genetic Features of Young Individuals With Colorectal Cancer.
    Stoffel EM; Koeppe E; Everett J; Ulintz P; Kiel M; Osborne J; Williams L; Hanson K; Gruber SB; Rozek LS
    Gastroenterology; 2018 Mar; 154(4):897-905.e1. PubMed ID: 29146522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.
    Desai A; Small EJ
    Future Oncol; 2019 Jul; 15(20):2337-2348. PubMed ID: 31184937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
    Casadei-Gardini A; Rimassa L; Rimini M; Yoo C; Ryoo BY; Lonardi S; Masi G; Kim HD; Vivaldi C; Ryu MH; Rizzato MD; Salani F; Bang Y; Pellino A; Catanese S; Burgio V; Cascinu S; Cucchetti A
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3665-3671. PubMed ID: 33745079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-decade patient with colorectal cancer carrying both germline and somatic mutations in APC gene.
    Yeh YS; Chang YT; Ma CJ; Huang CW; Tsai HL; Chen YT; Wang JY
    BMC Cancer; 2017 Dec; 17(1):849. PubMed ID: 29237421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
    Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
    Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
    Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
    Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.